| 查看: 4437 | 回复: 16 | ||||
wachina至尊木虫 (知名作家)
|
[交流]
武田fasiglifam (TAK-875)宣告失败，恒瑞呋格列泛齿亡唇寒 已有16人参与
|
|||
|
Takeda terminates development activities for fasiglifam (TAK-875) Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program. The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial. After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam. 作为慢性疾病：糖尿病的治疗，肝毒性太致命了，难怪武田挥泪斩马谡。值得一提的是，恒瑞也向CFDA申报了GPR-40激动剂呋格列泛，现在心里估计也是拔凉拔凉的 |
回复此楼» 收录本帖的淘帖专辑推荐
 新药仿药 |
» 猜你喜欢
阿西替尼杂质
已经有0人回复
-
盐酸贝西沙星
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有79人回复
-
姜黄烯杂质
已经有0人回复
-
克立硼罗
已经有0人回复
-
米拉贝隆
已经有0人回复
-
SPME-GC-O-MS
已经有0人回复
-
祈福面上能中
已经有141人回复
-
求Endnote官网关于《Avian Conservation and Ecology》杂志的.ens文件
已经有2人回复
-
国自然意见求助
已经有74人回复
3楼2013-12-30 13:06:43
4楼2013-12-30 16:49:55
mengdragon
木虫 (著名写手)
muchong
- 应助: 61 (初中生)
- 金币: 3372.3
- 散金: 54
- 红花: 13
- 帖子: 1806
- 在线: 356.2小时
- 虫号: 203914
- 注册: 2006-03-02
- 性别: GG
- 专业: 合成药物化学
6楼2013-12-30 22:13:49
2楼2013-12-30 12:41:43
| 哎！！！！！！！ |
5楼2013-12-30 17:02:55
091602
铁杆木虫 (小有名气)
- 应助: 65 (初中生)
- 金币: 11932.2
- 散金: 9
- 红花: 4
- 帖子: 203
- 在线: 2295.2小时
- 虫号: 826350
- 注册: 2009-08-12
- 性别: GG
- 专业: 药物合成
7楼2013-12-31 08:51:06
8楼2013-12-31 09:35:56
lu198799
金虫 (正式写手)
- 应助: 7 (幼儿园)
- 金币: 1362.5
- 散金: 2
- 帖子: 454
- 在线: 127.5小时
- 虫号: 775421
- 注册: 2009-05-20
- 性别: GG
- 专业: 合成药物化学
9楼2013-12-31 10:00:56
gwmgyp
版主 (知名作家)
搬砖将
- DRDEPI: 8
- 应助: 820 (博后)
- 贵宾: 3.006
- 金币: 17161.9
- 散金: 13
- 红花: 67
- 沙发: 1
- 帖子: 5612
- 在线: 944.5小时
- 虫号: 1272275
- 注册: 2011-04-21
- 专业: 药物分析
- 管辖: 新药研发
10楼2013-12-31 10:12:11